Clinical Trial

A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer

Study acronym: IGNITE-CRC
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of the concurrent combination therapy of S 531011 + fruquintinib or S 531011 + fruquintinib + pembrolizumab in patients with MSS/pMMR colorectal cancer.
Trial Details
NCT Number NCT07591597
Lead Sponsor National Cancer Center Hospital East
Collaborators: Shionogi
Conditions Metastatic Colorectal Neoplasms, Microsatellite Stable / Proficient Mismatch Repair Colorectal Cancer
Enrollment 68 participants
Start Date 2026-05
Primary Completion 2027-07 (estimated)
Study Completion 2029-05 (estimated)
Updated on ClinicalTrials.gov 2026-05-18